- Wave aims for monthly dosing with RNA editing treatment for AATDWave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. P…Endpoints · 2mo ago↗ source
- A migraine drugmaker heads to the public markets through reverse merger<figure><div><img src="https://imgproxy.divecdn.com/0Yf4L7bvFRwsrMG85EgRSmundmb9MCnHWX_B23e8BPk/g:nowe:0:0/c:3000:1694/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0…BioPharma Dive · 2mo ago↗ source
- Full-Life Technologies raises $150M; Quince's reboot with pulmonary drugPlus, news about Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB. Full-Life Technologies gets $150M: The radiotherapy company has raised $110 million in a Series D round…